In this episode of Base to Base Biotech, join our CEO, Sean A. MacDonald, in conversation with Jim Cornall as he explores our platform breakthroughs, pipeline progress, and clinical vision delivering new therapeutic options for patients with hard-to-treat diseases. Hear how strategic optionality and patient impact fuel our momentum. Listen now| Domain Therapeutics Group
Why do so many solid tumors resist even the most advanced immunotherapies? In Drug Target Review, our CSO Stephan Schann shared how we are addressing this challenge through our differentiated approach powered by deep expertise in GPCR biology, a proprietary platform, and a determination to transform patient outcomes. View article| Domain Therapeutics Group
BIO 2025 round up spotlights biotech's resilience and innovation reflecting Domain's precision-driven, patient-first approach| Domain Therapeutics Group
Drawing from years of dealmaking across North America and Europe, our CEO Sean A. MacDonald alongside other industry leaders shared insights on the leadership mindset and operational rigor behind effective transactions in Citeline’s In Vivo feature. View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
View article| Domain Therapeutics Group
Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to […]| Domain Therapeutics Group
Sean will drive the Company through its next phase of growth and bring its highly promising pipeline through clinical development He brings more than 20 years of senior executive experience in the life science industry across business development, operations, and strategy Strasbourg, France – Montreal, Canada – Boston, United States – April 17, 2024 […]| Domain Therapeutics Group
Anthony Johnson, President and Chief Executive Officer of Domain Therapeutics, and Sean A. MacDonald, Chief Business Officer to engage in key industry events in Q2 2024 Domain’s leadership will provide a corporate overview including advancements of key drug candidates in immuno-oncology: DT-9081 currently in Phase I ascending dose, as well as DT-7012 and DT-9045 in […]| Domain Therapeutics Group